EVGN
Evogene Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.37
−4.71%Year over year
Reported trailing growth
- Revenue
- -80.4%
- EBITDA
- -67.7%
- EBIT
- +23.5%
- EPS
- +59.5%
- Free cash flow
- +36.6%
- Operating cash flow
- +34.6%
Forward estimates
Based on analyst estimates
- Revenue
- -70.2%
- EBITDA
- +93.4%
- EPS
- +78.0%
Three-year CAGR
- Revenue
- +32.0%
- EBITDA
- +8.7%
- EBIT
- +25.4%
- Net income
- +48.5%
- EPS
- +62.6%
- Free cash flow
- +32.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026